Cannabis Law Report

FEBRUARY 16, 2022

A 28-page DEA report — authored in August of 2021, and based on Department of Health and Human Services reviews of these psychedelics from 2012 — states, “These five tryptamines have no known medical use in the United States and are not marketed internationally as approved drug products. Read full report at.

DEA 52

DEA Safety Treatment Law 52

CannaMD

JULY 19, 2020

Drug Enforcement Agency (DEA) made far fewer cannabis-related arrests in 2019 than in previous years. Let’s take a closer look at what DEA data reveals. But despite all the DEA’s seizing and destroying, it’s clear that the average U.S. That’s what DEA data indicates, at least — especially when looked at closely.

DEA 59

DEA Marijuana Data Decriminalization 59

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). Orphan Drug Designation?

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

SEPTEMBER 2, 2021

Court of Appeals for the Ninth Circuit dismissed a petition brought by a team of cannabis researchers, scientists, and military veterans to require that the Drug Enforcement Administration (DEA) reevaluate marijuana’s status as a Schedule I substance under the Controlled Substances Act (CSA). The case before the Ninth Circuit, Sidley v.

DEA 102

DEA Marijuana Treatment Legalization 102

Freedom Leaf

OCTOBER 15, 2018

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. schedules were created by the Controlled Substances Act (CSA) in 1970 and are interpreted and enforced by the DEA.

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

Canna Law Blog

JUNE 13, 2023

Drug Enforcement Administration (DEA) to implement and enforce the relevant provisions of the Controlled Substances Import and Export Act which makes it a crime to bring controlled substances into the country without a proper license. CBP coordinates with a wide range of partner government agencies (e.g., FDA, EPA, DOT, ATF, CPSC, etc.)

DEA 63

DEA Marijuana Hemp Concentrates 63

Cannabis Law Report

JULY 7, 2021

Pennington, who focuses on federal appeals and regulatory issues, is co-counsel on several high-profile cases against the DEA regarding cannabis research, hemp, and psychedelics. Circuit), a pending petition for review of DEA’s August 2020 Interim Final Rule purportedly implementing the 2018 Farm Bill’s amendments to the CSA.

DEA 111

DEA Hemp Cultivation Advocacy 111

Canna Law Blog

NOVEMBER 27, 2021

So according to the DEA, its abuse potential is high and it has no medical use. Also, according to the DEA, “the history of human experience probably goes back several hundred years since DMT usage is associated with a number of religious practices and rituals.” MDMA (Ecstasy) Nears FDA Approval for PTSD Treatment.

Therapy 88

Therapy Clinical Trials DEA Microdosing 88

Veriheal

AUGUST 23, 2023

A disputable new social media drug reporting bill believes that social media companies should screen client posts and report any drug-related exercises to the DEA. Senator Ron Wyden is unequivocally against this thought, profoundly worried that it could disregard individuals’ protection privileges and the right to speak freely.

Media 52

Media DEA Advocacy Legislation 52

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] 8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. Defining Psychedelics.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

United Patients Group

APRIL 3, 2023

Epidiolex, an FDA-approved medication containing CBD (cannabidiol), has been listed as Schedule 5 by the DEA since June 25th, 2019. The doctor who writes the prescription must be licensed and has to write it for a specific patient, as opposed to prescribing general instructions for treatment. Cannabis is a schedule 1 substance.

DEA 52

DEA Patients Conditions Cannabis 52

TheAnswerPage

APRIL 14, 2020

Epidiolex, a CBD product derived from the cannabis plant, received FDA approval for the treatment of Lenox Gastaut syndrome and Dravet syndrome in November 2018. Since Epidiolex is no longer a controlled substance, physicians are not required to notify the DEA when prescribing the medication. Is Epidiolex a controlled substance?

DEA 52

DEA Treatment Programs Medicine 52

CannaMD

AUGUST 8, 2020

Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential. CBD Scheduling Rule Change. But the government is clear. What can CBD do?

CBD 100

CBD DEA Research and Development Hemp 100

Veriheal

JUNE 30, 2023

Additionally, participants also reported feeling increased self-awareness and general improvement in relationships following their treatment. Lastly, the guide lays out the complex DEA registration process researchers much navigate to gain access to plants like psilocybin.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

SpeedWeed

JULY 23, 2021

Thanks to the new DEA research license, MedPharm will now be able to supply investigational medications across state lines for the purpose of clinical trials. The license only allows MedPharm to conduct research on cannabis that was shifted through certain channels that have been approved by the government and DEA.

Clinical Trials 52

Clinical Trials Research and Development DEA Cannabinoids 52

Veriheal

DECEMBER 28, 2021

D espite the Drug Enforcement Agency’s (DEA) announcement in May that it would soon start reviewing grower applications for research purposes, cannabis research continues to be tightly restricted. Over the last few decades, the cannabis plant and its many components have been the focal point of research and stiff debate.

Research and Development 98

Research and Development Chronic Pain Treatment Medicine 98

Cannabis Law Report

OCTOBER 5, 2021

“This shows that combination of psilocybin and music has a strong emotional effect, and we believe that this will be important for the therapeutic application of psychedelics if they are approved for clinical use,” said lead researcher Dea Siggaard Stenbæk , Associate Professor University of Copenhagen.

Clinical Trials 52

Clinical Trials Research and Development DEA Therapy 52

Cannabis Law Report

AUGUST 18, 2022

Smith , a partner with the firm and co-leader of the firm’s Life Sciences & Health Effects Team, will lead the practice, bringing together scientist-attorneys and experienced litigators to support clients that are driving innovation in mental health treatments. Tweet this. However, change appears imminent. ” Joining Ms.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

The Fresh Toast

APRIL 17, 2023

5 Facts About Glaucoma And Medical Marijuana Medical marijuana glaucoma treatment can help reduced eye pressure and relieve pain. Here's what you need to know about using cannabis for eye health. The post 5 Facts About Glaucoma And Medical Marijuana appeared first on The Fresh Toast.

Marijuana 98

Marijuana Treatment DEA Topical 98

Cannabis Law Report

OCTOBER 4, 2021

Accordingly, it cannot be prescribed by a physician and it is not legally accessible to those who might benefit from it as a therapeutic treatment. This is a policy where the federal government, the DEA, will refrain from taking prosecutorial action if state law permits, regulates, and carefully controls the use of a drug.

Therapy 52

Therapy Patients Law Clinical Trials 52

Canna Law Blog

OCTOBER 27, 2020

Still, even if the FDA approves a psilocybin drug and the Drug Enforcement Administration (DEA) reschedules the compound, the legal paradigm will be similar to what we see today: psilocybin will be classified as a controlled substance, unlawful prescribe without a DEA license. The Oregon program will not square with federal laws.

DEA 80

DEA Decriminalization Research and Development Programs 80

MedicalJane

JUNE 29, 2018

The new drug is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome. The Next Move Is On The DEA.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. Drug Enforcement Agency (“DEA”). Id ; 21 CFR 312.1-10; 10; 312.80-88; 88; 312.300 et seq.

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

NOVEMBER 9, 2019

That includes things like moving money out of the DEA and into overdose treatment programs, as well as really examining some of the ways that we can also decriminalize the use and study of psychedelic compounds for medicinal applications and future policies.”.

Decriminalization 45

Decriminalization DEA Policy Events 45

CannaMD

NOVEMBER 20, 2020

Making matters worse, there’s only one farm in the entire country with DEA approval to cultivate marijuana for research purposes. On a scale of 1-10, how ironic is it that the most effective treatment for using too much marijuana might be… marijuana? For more details, see: Best Cannabis Disorder Treatment? More Cannabis.

Therapy 80

Therapy Treatment DEA CBD 80

FloridaMarijuana.net

JULY 8, 2018

The study has received full approval from the FDA, DEA, and Institutional Review Boards (IRBs). While there is a popular belief that Indica strains are the best treatment, a variety of genetics (Hybrid, Sativa, CBD) may alleviate the symptoms of PTSD. 5 cannabis strains to treat PTSD: 1.

Strains 190

Strains Indica Hybrid Research and Development 190

Burns Levinson (Cannabusiness advisory)

OCTOBER 3, 2018

This marks the first time in history that the DEA has removed any type of cannabis from Schedule I, and clears the way for the sale of the first non-synthetic, cannabis-derived medicine to win federal approval. Epidiolex is an oral solution that contains CBD, and is also the first FDA-approved drug derived directly from the cannabis plant.

CBD 40

CBD DEA Epilepsy Pharmaceutical 40

SpeedWeed

AUGUST 8, 2021

Sativex (sold as nabiximols or Epidiolex in the United States) is manufactured by British company GW Pharmaceuticals, which received full federal approval in its home country for the drug back in 2010 for the treatment of multiple sclerosis. For years, such studies were largely blocked by prohibition-committed government entities. .

Cannabinoids 64

Cannabinoids Pharmaceutical DEA Medicine 64

Veriheal

AUGUST 24, 2022

If passed, the Department of Regulatory Agencies would be required to develop rules that would allow for therapeutic psychedelic programs at licensed healing centers for adults to receive psychedelic treatments by a trained facilitator.

Legalization 109

Legalization Decriminalization Medicine Research and Development 109

Cannabis Law Report

MARCH 2, 2020

Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to Compass Pathways ‘ psilocybin therapy for treatment-resistant depression. First up, cannabis has now been scientifically validated as a treatment for two severe forms of childhood epilepsy (more on this in a moment). In 2018, the U.S.

Medicine 59

Medicine Therapy DEA Pharmaceutical 59

Cannabis Law Report

JUNE 11, 2021

Without a doubt, physicians need DEA licenses to prescribe and administer ketamine, but the clinic may also need its own DEA license and/or registration (see here ) for drug storage and/or additional and/or multiple state clinic licenses that range from outpatient drug treatment to just general health care facilities.

Law 104

Law Compliance Compliance DEA 104

Cannabis Law Report

JANUARY 28, 2022

Marijuana myths continue to keep people from trying medical marijuana as a treatment. A lot of people think it just gets you high, but for many, it is actually a treatment that provides relief and not just a euphoric high,” she said. “I Marijuana Myths Continue to Hinder What Marijuana Can Do. It’s not.”.

Marijuana 52

Marijuana DEA Treatment Sleep 52

Cannabis Law Report

NOVEMBER 20, 2021

Drug Enforcement Administration (DEA), the Alabama Prescription Drug Monitoring Program maintained by Alabama Department of Public Health, and the Alabama Medical Cannabis Patient Registry System maintained by the Alabama Medical Cannabis Commission. Obtaining this permit requires the physician to: complete an application. 31 each year.

Patients 52

Patients DEA Dispensary Conditions 52

Veriheal

APRIL 11, 2022

Drug Enforcement Agency (DEA). According to the company’s CEO, George Hodgin, “federally legal FDA- and DEA-approved cannabis-based drugs will absolutely upend the traditional pharmaceutical market.”. Groff confirmed that it had completed its first batch of medicinal-grade cannabis for research purposes on Feb.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

SpeedWeed

MAY 15, 2021

For 88% of people who receive this treatment, we can expect to see a treatment response. The therapists and expert research team who have brought us here are at the vanguard of what may be a revolution in mental health care,” said Michael Mithoefer, MD, who trained the 70 therapists who provided the treatment in this study.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Medicinal Genomics

JULY 13, 2023

one of just seven federally DEA- licensed cannabinoid research labs, had some encouraging news about how cannabinoids and cannaflavins can lengthen life spans while improving health spans. Watch Dr. Russo’s Presentation Hunter Land, Ph.D, the VP of Research & Development at Biopharmaceutical Research Company, Inc.,

Research and Development 52

Research and Development Cannabinoids DEA Medicine 52